These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 19825819)
1. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819 [TBL] [Abstract][Full Text] [Related]
2. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis. Aguiar MG; Pereira AM; Fernandes AP; Ferreira LA Antimicrob Agents Chemother; 2010 Nov; 54(11):4699-704. PubMed ID: 20713665 [TBL] [Abstract][Full Text] [Related]
3. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis. de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991 [TBL] [Abstract][Full Text] [Related]
4. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. Grogl M; Schuster BG; Ellis WY; Berman JD J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319 [TBL] [Abstract][Full Text] [Related]
5. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice. Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice. Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653 [TBL] [Abstract][Full Text] [Related]
7. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684 [TBL] [Abstract][Full Text] [Related]
8. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions. Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476 [TBL] [Abstract][Full Text] [Related]
9. In vivo activity of perifosine against Leishmania amazonensis. Cabrera-Serra MG; Valladares B; Piñero JE Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328 [TBL] [Abstract][Full Text] [Related]
10. Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. Gonçalves GS; Fernandes AP; Souza RC; Cardoso JE; de Oliveira-Silva F; Maciel FC; Rabello A; Ferreira LA Acta Trop; 2005 Feb; 93(2):161-7. PubMed ID: 15652330 [TBL] [Abstract][Full Text] [Related]
11. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. Carneiro G; Santos DC; Oliveira MC; Fernandes AP; Ferreira LS; Ramaldes GA; Nunan EA; Ferreira LA J Liposome Res; 2010 Mar; 20(1):16-23. PubMed ID: 19530897 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. Trinconi CT; Reimão JQ; Coelho AC; Uliana SR J Antimicrob Chemother; 2016 May; 71(5):1314-22. PubMed ID: 26851606 [TBL] [Abstract][Full Text] [Related]
13. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. Garnier T; Mäntylä A; Järvinen T; Lawrence J; Brown M; Croft S J Antimicrob Chemother; 2007 Oct; 60(4):802-10. PubMed ID: 17715126 [TBL] [Abstract][Full Text] [Related]
15. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Mussi SV; Fernandes AP; Ferreira LA Parasitol Res; 2007 May; 100(6):1221-6. PubMed ID: 17206508 [TBL] [Abstract][Full Text] [Related]
16. Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice. Kavian Z; Alavizadeh SH; Golmohamadzadeh S; Badiee A; Khamesipour A; Jaafari MR Acta Trop; 2019 Aug; 196():142-149. PubMed ID: 31103698 [TBL] [Abstract][Full Text] [Related]
17. Leishmania major: bacterial contamination of cutaneous lesions in experimental animals. el-On J; Sneier R; Elias E Isr J Med Sci; 1992 Dec; 28(12):847-51. PubMed ID: 1286954 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of anti-leishmanial activity by induction of nitric oxide and inhibition of prostaglandin in Balb/c mice infected with Leishmania major. Nahrevanian H; Hajihosseini R; Arjmand M; Farahmand M; Ghasemi F Southeast Asian J Trop Med Public Health; 2009 Nov; 40(6):1188-98. PubMed ID: 20578452 [TBL] [Abstract][Full Text] [Related]
19. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Shazad B; Abbaszadeh B; Khamesipour A Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817 [TBL] [Abstract][Full Text] [Related]
20. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model. Van Bocxlaer K; Yardley V; Murdan S; Croft SL J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]